Sernova, Evotec Join Forces To Develop 'Functional Cure' For Diabetes

  • Sernova Corp and Evotec SE EVO have announced an exclusive global strategic partnership to develop cell therapy treatment for insulin-dependent diabetes. 
  • The companies will leverage their respective technologies and scientific expertise to develop an implantable iPSC-based (induced pluripotent stem cells) beta cell replacement therapy.
  • The partnership provides Sernova a global exclusive option to license Evotec's iPSC-based beta cells to treat both type 1 and type 2 diabetes. 
  • Also Read: Why Are Evotec Shares Trading Lower On Friday?
  • In addition to entering into the collaboration agreement, Evotec has made a strategic equity investment of €15 million and will further invest €5 million. 
  • Concurrently, Evotec acquired 12.9 million shares at C$1.57 per share for gross proceeds to Sernova of C$20.3 million. 
  • In addition, Evotec will acquire a further 2.7 million shares at C$2.50 per share for gross proceeds of $6.8 million.
  • Evotec's Chief Scientific Officer, Cord Dohrmann, will join Sernova's Board of Directors.
  • Price Action: EVO shares are trading at $12.61 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareContractsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!